Part 2: Structure–activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase
摘要:
A novel class of pyrazolopyridazine p38 alpha mitogen-activated protein kinase (MAPK) inhibitors is disclosed. A structure activity relationship (SAR) investigation was conducted driven by the ability of these compounds to inhibit the p38a enzyme, the secretion of TNF alpha in a LPS-challenged THP1 cell line and TNF alpha-induced production of IL-8 in the presence of 50% human whole blood (hWB). This study resulted in the discovery of several inhibitors with IC50 values in the single-digit nanomolar range in hWB. Further investigation of the pharmacokinetic profiles of these lead compounds led to the identification of three potent and orally bioavailable p38 alpha inhibitors 2h, 2m, and 13h. Inhibitor 2m was found to be highly selective for p38 alpha/beta over a panel of 402 other kinases in Ambit screening, and was highly efficacious in vivo in the inhibition of TNF alpha production in LPS-stimulated Lewis rats with an ED50 of ca. 0.08 mg/kg. (C) 2010 Elsevier Ltd. All rights reserved.
Heterocyclic Compounds As CCR1 Receptor Antagonists
申请人:Cook Brian Nicholas
公开号:US20120270879A1
公开(公告)日:2012-10-25
Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).
Heterocyclic compounds as CCR1 receptor antagonists
申请人:Cook Brian Nicholas
公开号:US08927550B2
公开(公告)日:2015-01-06
Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).
HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
申请人:Boehringer Ingelheim International GmbH
公开号:EP2493875B1
公开(公告)日:2014-08-06
US8927550B2
申请人:——
公开号:US8927550B2
公开(公告)日:2015-01-06
[EN] HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR1
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2011056440A1
公开(公告)日:2011-05-12
Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).